VeriMompalmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine est-il sûr pendant la grossesse ?
No harmonised CLP classification or SCCS/CIR reproductive safety restriction was found for this ingredient. No peer‑reviewed reproductive or developmental toxicity data were identified. As a large palmitoyl‑peptide used topically, dermal absorption is expected to be negligible, and there is no structural or mechanistic evidence of reproductive toxicity. Sources consulted include PubChem, CosIng, PubMed (no reproductive studies), ECHA (no Annex VI harmonised classification), and EWG.
Pregnancy-safe products containing palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine
Related ingredients
Frequently asked questions
- palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine est-il sûr pendant la grossesse ?
- No harmonised CLP classification or SCCS/CIR reproductive safety restriction was found for this ingredient. No peer‑reviewed reproductive or developmental toxicity data were identified. As a large palmitoyl‑peptide used topically, dermal absorption is expected to be negligible, and there is no structural or mechanistic evidence of reproductive toxicity. Sources consulted include PubChem, CosIng, PubMed (no reproductive studies), ECHA (no Annex VI harmonised classification), and EWG.
- palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine est-il sûr pendant l'allaitement ?
- No data indicating transfer into breast milk or lactation-related toxicity. Given the peptide's size/polarity and expected negligible systemic absorption after topical use, risk of exposure to breastfed infants is unlikely. No regulatory flags (ECHA Annex VI, SCCS, CIR) or peer‑reviewed evidence were found.
- palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine est-il sûr pour la peau de bébé ?
- No infant‑specific reproductive or toxicology data located. Adult dermal absorption is expected negligible; however, infant skin has a higher surface‑area‑to‑weight ratio and immature barrier, so exposure score is increased by +1 for 0–3 yr. There is still no mechanistic or hazard evidence suggesting reproductive or developmental toxicity for infants.
- Comment VeriMom évalue-t-il palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine ?
- VeriMom évalue palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine à 100/100 (pas de risques connus) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.